Politicizing Bayh-Dole ‘march-in’ rights will chill public-private R&D collaboration & stifle future innovation. Worse still, it won’t result in lower out-of-pocket Rx costs. Cynically, it distracts from needed insurance reforms that result in actual savings for U.S. consumers.